Literature DB >> 1726163

Current prevalence of hepatitis B, A and C in a healthy Spanish population. A seroepidemiological study.

R Dal-Ré1, L Aguilar, P Coronel.   

Abstract

A seroepidemiological study was carried out in order to determine the prevalence of markers of viral hepatitis infection in employees of five health-care companies and their cohabiting family members. Each participating family unit was required to fill out a questionnaire, in which, among other data, the employee was requested to indicate his or her job category. Markers of hepatitis B infection (anti-HBs, anti-HBc or HBsAg) were observed in 11.7% (58/497) of all subjects. When employees and family members were analysed according to the employee's job category, significant differences were found between "staff" (3%) and "administrative personnel" (13.3%; p less than 0.01) or "factory workers" (16.9%; p less than 0.01). Of 489 individuals tested for the presence of anti-HAV and anti-HCV, 59.1% and 0.6% respectively, were positive. There was a correlation between the prevalence of anti-HAV and age; a large proportion of the subjects under the age of 30 years had no evidence of prior HAV infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1726163     DOI: 10.1007/bf01726451

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  16 in total

1.  Antibodies to hepatitis C virus in French blood donors.

Authors:  C Janot; A M Couroucé; M Maniez
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

2.  Antibodies to hepatitis C virus in Italian blood donors.

Authors:  G Sirchia; A Bellobuono; A Giovanetti; M Marconi
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

3.  Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.

Authors:  J Bruix; J M Barrera; X Calvet; G Ercilla; J Costa; J M Sanchez-Tapias; M Ventura; M Vall; M Bruguera; C Bru
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

4.  [Intrafamilial diffusion of the hepatitis B virus. A study of familial contacts of chronic carriers].

Authors:  J Genescá; J I Esteban; R Esteban; M Butí; R Muñiz; G Seijo; J M Hernández; J Guardia
Journal:  Med Clin (Barc)       Date:  1986-09-13       Impact factor: 1.725

5.  Acquisition of antibody to hepatitis B antigen in three socioeconomically different medical populations.

Authors:  C E Cherubin; R H Purcell; J J Lander; T G McGinn; L A Cone
Journal:  Lancet       Date:  1972-07-22       Impact factor: 79.321

6.  [Attitude of high-risk personnel to a hepatitis B vaccination campaign in a general hospital].

Authors:  G San Miguel; R Ortiz de Diego; M J Cabero; E Fernández Felgueroso; J L Carrasco; R Lardinois; F Pons Romero
Journal:  Med Clin (Barc)       Date:  1988-03-05       Impact factor: 1.725

7.  [Serologic markers for hepatitis B virus in a group of healthy individuals (author's transl)].

Authors:  V Vargas; J D Pedreira; R Esteban; J M Hernández; J Piqueras; J Guardia
Journal:  Med Clin (Barc)       Date:  1982-04-01       Impact factor: 1.725

8.  Anti-hepatitis-A antibody in Spain.

Authors:  V Vargas; R Esteban; J D Pedreira; J Viladoms; J M Hernandez; J Guardia
Journal:  Lancet       Date:  1978-09-09       Impact factor: 79.321

9.  Seroepidemiology of hepatitis B virus infection in the United States. 1976 to 1980.

Authors:  G M McQuillan; T R Townsend; H A Fields; M Carroll; M Leahy; B F Polk
Journal:  Am J Med       Date:  1989-09-04       Impact factor: 4.965

10.  Distribution of antibody to hepatitis a antigen in urban adult populations.

Authors:  W Szmuness; J L Dienstag; R H Purcell; E J Harley; C E Stevens; D C Wong
Journal:  N Engl J Med       Date:  1976-09-30       Impact factor: 91.245

View more
  5 in total

1.  Seroprevalence of hepatitis B and C in subjects admitted to a cardiology clinics in Turkey.

Authors:  O Ozdemir; K Arda; M Soylu; O Alyan; A D Demir; E Kütük
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

2.  Cost effectiveness of hepatitis A virus immunisation in Spain.

Authors:  J M Arnal; O Frisas; R Garuz; F Antoñanzas
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

3.  Safety and immunogenicity of an inactivated hepatitis A vaccine in children 2 to 5 years old.

Authors:  J Arístegui; J L Morales; R Dal-Ré; A González; M S Gallego; E Garrote
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

4.  Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees.

Authors:  V Sypsa; E Hadjipaschali; A Hatzakis
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

5.  Prevalence of anti-HCV and risk factors for hepatitis C virus infection in healthy pregnant women.

Authors:  F Marranconi; P Fabris; C Stecca; L Zampieri; M C Bettini; N Di Fabrizio; F de Lalla
Journal:  Infection       Date:  1994 Sep-Oct       Impact factor: 3.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.